Health Economics›Non-small cell lung cancer›Adjuvant therapy

Adjuvant therapy

Non-small cell lung cancer · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~8.4 mo	~21.9 mo	~19	~R 5 452 150 PFS proxy · indirect	11
Osimertinib monotherapy Variant #01	EGFR	R 77 777	28d	—	—	—	—	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	~13.3 mo	—	—	4
Cisplatin and Gemcitabine (GC) Variant #34	ALK	R 15 338	56d	—	—	—	—	1
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	—	—	—	1
Gefitinib monotherapy Variant #01	EGFR	R 8 556	28d	~9.7 mo	~17.0 mo	~11	~R 94 111 PFS proxy · indirect	27
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	—	95.0 mo	—	—	1
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	—	—	—	—	1
Cisplatin and Vinorelbine (CVb) Variant #11	ALK	R 4 117	42d	—	79.9 mo	—	—	3
Cisplatin and Vinorelbine (CVb) Variant #11	EGFR	R 4 117	42d	—	79.9 mo	—	—	3
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	79.9 mo	—	—	3
Carboplatin and Gemcitabine (GCb) Variant #01	ALK	R 3 663	21d	~5.6 mo	~10.0 mo	~9	~R 32 967 PFS proxy · indirect	11
Cisplatin and Vinblastine Variant #03	—	R 1 973	28d	—	—	—	—	1
Cisplatin and Vindesine Variant #05 Partial	—	R 1 800	63d	—	—	—	—	1
Carboplatin and Vinorelbine Variant #01	ALK	R 1 609	21d	—	~6.7 mo	—	—	1
Cisplatin and Pemetrexed Variant #01	ALK	R 1 088	21d	~5.6 mo	~14.1 mo	~9	~R 9 788 PFS proxy · indirect	25
Cisplatin and Pemetrexed Variant #01	—	R 1 088	21d	~5.6 mo	~14.1 mo	~9	~R 9 788 PFS proxy · indirect	25
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	—	—	—	—	1
Alectinib monotherapy Variant #01	ALK	R 108	28d	~27.0 mo	—	~30	~R 3 229 PFS proxy · indirect	7
Carboplatin and Pemetrexed N/A - secondary systemic drug	ALK	R 52	21d	~5.6 mo	~13.8 mo	~9	~R 469 PFS proxy · indirect	25
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.2 mo	~13.3 mo	~10	—	3
Placebo Partial	EGFR	—	—	—	—	—	—	2
UFT monotherapy Variant #04 Partial	—	—	28d	—	—	—	—	1
Placebo Partial	—	—	—	—	—	—	—	2
Tegafur and uracil monotherapy Partial	—	—	—	—	—	—	—	—
Observation Partial	—	—	—	—	60.5 mo	—	—	4
Radiation therapy N/A - radiation Partial	—	—	49d	~5.1 mo	~12.0 mo	~4	—	1
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	—	—	—	—	2

28 of 28 regimens shown